PRA Health Sciences

ICON Announces CFO Transition

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Medical Devices, Health, Finance, Pharmaceutical, Biotechnology, ICON PLC, Pleasure, ICLR, PRA Health Sciences, Growth, CFO, Management

Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.

Key Points: 
  • Brendan has held the role since 2012 and will remain with the company in his current role as CFO to ensure a smooth transition to a newly appointed Chief Financial Officer.
  • ICON has commenced a search to identify the next CFO.
  • “On behalf of the ICON Board and Leadership Team, I want to thank Brendan for his strong contributions to ICON over his 18 years, including 12 years as CFO,” said Steve Cutler, ICON’s CEO.
  • We have commenced a search to identify our next CFO and will update on that process at the appropriate time.

Linden Capital Partners and Ontario Teachers’ Pension Plan Launch Initiative Focused on Clinical Research Advancement

Retrieved on: 
Thursday, February 8, 2024
Health, Practice Management, Other Health, General Health, Research, Science, Biotechnology, CDISC, Head, PRA Health Sciences, Chairperson, IQVIA, Patient, PPD, Pharmaceutical industry

Linden Capital Partners (Linden) and Ontario Teachers’ Pension Plan (Ontario Teachers’) are pleased to announce they are partnering on a transformative platform, led by Dr. John Potthoff , with the goal of revolutionizing the clinical research ecosystem.

Key Points: 
  • Linden Capital Partners (Linden) and Ontario Teachers’ Pension Plan (Ontario Teachers’) are pleased to announce they are partnering on a transformative platform, led by Dr. John Potthoff , with the goal of revolutionizing the clinical research ecosystem.
  • This strategic initiative is centered around investing in exceptional companies and deploying cutting-edge technology to foster seamless connections and collaborations among patients, research sites, pharmaceutical companies, and the broader clinical research community.
  • The platform will be led by Dr. John Potthoff, who is currently the Chairperson of Elligo Health Research ®.
  • Our commitment is to address these challenges head-on and catalyze positive change in our industry.”
    Vision for a Unified Clinical Research Ecosystem: The initiative is dedicated to building a more unified and efficient clinical research ecosystem.

ObvioHealth Strengthens Leadership Team with Key Industry Appointments

Retrieved on: 
Tuesday, October 17, 2023
Multimedia, Acquisition, Drug development, Clinical data management, PRA Health Sciences, King's College, Genetic, Labcorp, Health, Doctor of Philosophy, Parallel, VRO, Cassidy, Growth, Clinical trial, Commercial, United States Department of the Army, Nursing, Science

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- ObvioHealth, a virtual research organization (VRO) delivering stronger clinical evidence through tech-enabled trials, announces the appointment of John Cassidy as its new Chief Financial Officer and Florence Mowlem as Vice President of Science. The two industry veterans will reinforce the company's clinical and digital trial expertise.

Key Points: 
  • The two industry veterans will reinforce the company's clinical and digital trial expertise.
  • At ObvioHealth, he will work alongside the executive team to develop robust financial infrastructure, controls, and planning.
  • Florence Mowlem, Vice President of Science, comes to ObvioHealth from Medable, where she led a team driving the implementation of electronic clinical outcomes assessments (eCOAs).
  • "I hope to help shape the company's scientific strategy to put ObvioHealth at the forefront of life-improving clinical research practices."

ICON Secures Upgraded Credit Rating from S&P Global Ratings

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, S&P, ICON PLC, S&P Global Ratings, PRA Health Sciences, ICLR, Risk management, ICON

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.
  • S&P upgraded ICON from a ‘BB+’ rating to a ‘BBB-’, raising their long-term issuer credit rating and their issue rating on the group’s senior secured term debt.
  • S&P highlighted in their report, “ICON’s solid operating performance and voluntary debt prepayments improve credit metrics to a level commensurate with an investment-grade rating”.
  • Brendan Brennan, Chief Financial Officer, commented: “We are proud of the investment grade rating upgrade from S&P, which is aligned with our stated long-term capital allocation priorities for ICON, and indicative of the strong financial position of the company.

Meeting Protocol Worldwide Expands Leadership Team with Four New Appointments

Retrieved on: 
Monday, October 9, 2023
University, Senior, Data science, Hospital, MBA, Acquisition, Kellogg School, Master of Science in Management, PRA Health Sciences, Berkeley, SVKM's NMIMS, Culture, University of North Carolina at Charlotte, Bayer, Chapel Hill, Industrial, Doctor of Philosophy, Environment, Growth, Marketing, The arts, Software, Executive, Actigraphy, University of Liverpool, Scout (operating system), Management, Pfizer, Science

"At Meeting Protocol Worldwide, we are proud of the incredible talent we have added to our leadership team, who will take us into our next phase of growth with clients across the globe.

Key Points: 
  • "At Meeting Protocol Worldwide, we are proud of the incredible talent we have added to our leadership team, who will take us into our next phase of growth with clients across the globe.
  • Each of these individuals brings with them decades of experience in sales, marketing, operations, and finance," said Paige Bingham, CEO, Meeting Protocol Worldwide.
  • Kuno van der Post, Ph.D., serves as Chief Revenue Officer, where he spearheads marketing and sales efforts across the Meeting Protocol Worldwide family of brands.
  • Mr. Fontenault's additional experience includes leadership positions at ER Squared, INC.; Kendle International, Pfizer, EResearchTechnology, Purdue Pharma L.P., and Bayer Healthcare.

Syneos Health Appoints Colin Shannon as Chief Executive Officer

Retrieved on: 
Tuesday, October 3, 2023
IPO, Tesco international operations, EVP, Shannon, ICON, Sale, Organization, Syneos Health, PRA Health Sciences, Administration, Colin, CFO, Growth, Keefe, ICON PLC, Management

MORRISVILLE, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that Colin Shannon has been appointed Chief Executive Officer, effective immediately.

Key Points: 
  • MORRISVILLE, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that Colin Shannon has been appointed Chief Executive Officer, effective immediately.
  • Shannon succeeds Michelle Keefe, who will continue her tenure with Syneos Health as a key member of the Executive Leadership Team.
  • During his 14 years at PRA Health Sciences, Shannon served in executive roles, most recently as Chairman and CEO.
  • “It is an honor to be tasked with leading Syneos Health at such an exciting time in its evolution,” said Shannon.

Biotech Executive Michael Smith Discusses the FDA Drug Development Process with CancerVAX CEO Ryan Davies

Retrieved on: 
Friday, June 16, 2023
Biotechnology, BS, Drug development, Doctor of Pharmacy, University, Senior, Cancer, CancerVax, Immunotherapy, Development, PRA Health Sciences, Knowledge, Growth, FDA, BYU, Pharmaceutical industry, Pharmacy, Neuroscience, LEHI

LEHI, Utah, June 16, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its CEO, Ryan Davies and biotech executive Michael Smith recently discussed the FDA drug development process and the growth of immunotherapy treatments.

Key Points: 
  • LEHI, Utah, June 16, 2023 (GLOBE NEWSWIRE) -- CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, today announced that its CEO, Ryan Davies and biotech executive Michael Smith recently discussed the FDA drug development process and the growth of immunotherapy treatments.
  • “Immunotherapy, of course, has made a tremendous leap and I think that it will continue to do so,” said Mr. Smith.
  • “It was insightful and delightful speaking with Mike,” said CancerVax CEO, Ryan Davies.
  • It’s been fun to watch him ascend into meaningful roles in the biotech space.”
    For more information about CancerVAX, please visit http://www.cancervax.com .

Precision Medicine Group Welcomes New General Counsel and Chief Compliance Officer and Chief People Officer

Retrieved on: 
Wednesday, April 26, 2023
PMG, Psychology, Human resources, Industrial and organizational psychology, Drug development, University, Senior, General counsel, IQVIA, Culture, Abbott, Springfield College, Personalized medicine, Cornell Law School, Risk management, Record, KKR, Precision, Hamilton College, Millennium, PRA Health Sciences, Patient, Ethics, Growth, University of Wisconsin–Stevens Point, Pfizer, Nursing, Management

BETHESDA, Md., April 26, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointments of Stacey Hanna, General Counsel and Chief Compliance Officer, and Tina Durocher-Murphy, Chief People Officer. In these roles, Stacey and Tina are responsible for all legal and compliance and human resources functions, respectively, across the enterprise. Both leaders will report directly to Mark Clein, Chief Executive Officer of Precision Medicine Group.

Key Points: 
  • Stacey Hanna, General Counsel and Chief Compliance Officer, leads all legal and compliance functions across Precision Medicine Group
    Tina Durocher-Murphy, Chief People Officer, is charged with fostering a culture committed to growth, teamwork, professional development, and improving patient lives
    BETHESDA, Md., April 26, 2023 /PRNewswire/ -- Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointments of Stacey Hanna, General Counsel and Chief Compliance Officer, and Tina Durocher-Murphy, Chief People Officer.
  • Both leaders will report directly to Mark Clein, Chief Executive Officer of Precision Medicine Group.
  • "As Precision Medicine Group innovates and evolves, adding senior-level talent like Tina and Stacey contributes significantly to scaling people, process, and culture for our next phase of growth," said Clein.
  • Prior to joining PMG, Stacey was the Vice President and General Counsel, Global Ethics & Compliance at Lonza.

ProSciento Appoints David Sockolof as Chief Financial Officer

Retrieved on: 
Thursday, February 2, 2023
MBA, CFO, Health, Labcorp Drug Development, Human, Therapy, Process optimization, DSM-IV codes, PRA Health Sciences, Business operations, George Washington University, Child, Labcorp, Heart, PRA, Growth, SAN, Management

SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on metabolic diseases, today announced the appointment of David Sockolof to the role of Chief Financial Officer (CFO).

Key Points: 
  • SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on metabolic diseases, today announced the appointment of David Sockolof to the role of Chief Financial Officer (CFO).
  • Mr. Sockolof joins ProSciento with an extensive track record in leading finance and business operations at global clinical research companies, including leadership roles at Labcorp Drug Development and PRA Health Sciences.
  • "His appointment as CFO further strengthens our executive leadership at an exciting time of growth for our team, our services, and our differentiators.
  • His most recent role was as Executive Director of Resource and Process Optimization at Labcorp Drug Development where he provided leadership in financial forecasting, expense management, and global resource management.

PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT

Retrieved on: 
Thursday, January 26, 2023
Southern Illinois University, University, Personalized medicine, Master of Health Administration, Fulling, PVH, Precision, Tulane University, PRA Health Sciences, Bachelor of Science, Growth, Organization, Doug Perlman, Creativity, PRA, Senior, Management, Symphony, Science

BETHESDA, Md., Jan. 26, 2023 /PRNewswire/ -- Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.

Key Points: 
  • BETHESDA, Md., Jan. 26, 2023 /PRNewswire/ -- Precision Value & Health (PVH) , today announces that Doug Fulling has joined as President.
  • Mark Clein, Precision Medicine Group's CEO, said, "We are thrilled to have Doug join our team.
  • Before joining Precision, Fulling served as President of Symphony Health where they reengineered a $250M data and analytics business to achieve double digit, top and bottom-line growth in less than three years.
  • Fulling earned his Bachelor of Science from Southern Illinois University and Master of Health Administration from Tulane University.